Lake Street lowered the firm’s price target on Tela Bio (TELA) to $3 from $6 and keeps a Buy rating on the shares following Q3 results that “were short of the Street” and 2025 and 2026 guidance that was down on prolonged sales force disruption. The firm believes shares could be range bound in the near-term, but also thinks the recapped balance sheet and reset outlook will “provide the team an opportunity to exceed expectations,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELA:
- Strategic Initiatives and Financial Adjustments Underpin Buy Rating for TELA Bio Despite Short-term Challenges
- Tela Bio price target lowered to $4 from $7 at Canaccord
- TELA Bio’s Earnings Call: Growth Amid Challenges
- TELA Bio Secures $70M Loan for Growth Initiatives
- Tela Bio price target lowered to $1.25 from $2 at Piper Sandler
